Last checked at 28 Jun 2023 12:01
28 June 2023
Cizzle Biotechnology Holdings Plc
("Cizzle Biotechnology" or the "Company")
Result of AGM
Cizzle Biotechnology, the UK-based diagnostics developer, announces that at the Annual General Meeting ("AGM") of the Company held earlier today, all resolutions were voted on by a show of hands and were passed.
The proxy votes cast in respect of the resolutions were as follows:
Resolution | For | Against | Votes withheld | ||
Total votes | % | Total votes | % |
| |
1. To receive the Company's annual report and accounts for the year ended 31 December 2022 | 89,757,080 | 97.11 | 2,672,935 | 2.89 | 1,661,693 |
2. To approve the Directors' Remuneration Report |
88,827,568
| 96.10 | 3,602,447 | 3.90 | 1,661,693 |
3. To re-appoint Allan John Syms as a Director of the Company |
88,827,578
| 96.14 |
3,568,237
| 3.86 | 1,695,893 |
4. To re-appoint PKF Littlejohn LLP as auditor of the Company | 88,861,778 | 96.14 | 3,568,237 | 3.86 |
1,661,693
|
5. To authorise the Directors to determine the auditor's remuneration | 88,861,778 | 96.14 | 3,568,237 | 3.86 |
1,661,693
|
6. Authorises the Directors to allot shares in the Company or to grant rights to subscribe for, or to convert any security into, shares in the Company | 88,661,778 | 95.92 | 3,768,237 | 4.08 | 1,661,693 |
7. Authorise the Directors to allot equity securities disapplying pre-emption rights | 88,823,568 | 96.10 | 3,606,437 | 3.90 | 1,661,703 |
8. That General Meetings may be called on not less than 14 days' notice | 88,861,778 | 96.14 | 3,568,237 | 3.86 | 1,661,693 |
Enquiries:
Cizzle Biotechnology Holdings plc | Via IFC Advisory |
Allan Syms (Executive Chairman) |
Allenby Capital Limited | +44(0) 20 33285656 |
John Depasquale | |
Alex Brearley |
Novum Securities Limited | +44(0) 20 7399 9400 |
Colin Rowbury Jon Bellis |
IFC Advisory Limited | +44(0) 20 3934 6630 |
Tim Metcalfe | cizzle@investor-focus.co.uk |
Florence Chandler |
Notes to Editors:
About Cizzle Biotechnology
Cizzle Biotechnology is developing a blood test for the early detection of lung cancer. Cizzle Biotechnology is a spin- out from the University of York, founded in 2006 around the work of Professor Coverley and colleagues. Its proof-of-concept prototype test is based on the ability to detect a stable plasma biomarker, a variant of CIZ1 known as CIZ1B. CIZ1 is a naturally occurring cell nuclear protein involved in DNA replication, and the targeted CIZ1B variant is highly correlated with early-stage lung cancer.
For more information, please see https://cizzlebiotechnology.com
You can also follow the Company through its twitter account @CizzlePlc and on LinkedIn.